Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00122694|
Recruitment Status : Completed
First Posted : July 22, 2005
Last Update Posted : September 12, 2006
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Disease, Chronic Obstructive||Drug: carbon monoxide||Phase 2|
COPD is characterised by a chronic pulmonary inflammation and a shifted oxidant/antioxidant balance. The main cause of this inflammation is smoking. After smoking cessation, this inflammation and shifted oxidant/antioxidant balance continues. This causes an increased deterioration of lung function compared to healthy persons of matching age.
The ongoing inflammation appears to be relatively insensitive to corticosteroid therapy.
Until now, there is no therapy for this inflammation. Both in vitro and in vivo studies show that carbon monoxide has, besides an antioxidant capacity, anti-inflammatory properties. The aim of this trial is to study whether the inflammation can be reduced by inhalation of carbon monoxide.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable COPD|
|Study Start Date :||January 2005|
|Estimated Study Completion Date :||March 2006|
- percentage of neutrophils in induced sputum
- methacholine provocation threshold
- exhaled CO/NO
- FEV1, FVC, RAW, sgaw
- inflammatory parameters in sputum and blood
- 8-isoprostane in exhaled breath
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00122694
|University Medical Center Groningen, Department of Pulmonary Diseases|
|Groningen, Netherlands, 9700RB|
|Principal Investigator:||H AM Kerstjens, Prof., MD, PhD||University Medical Center Groningen, Department of Pulmonary Diseases|